{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:31:15Z","timestamp":1784237475528,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["0065353"],"award-info":[{"award-number":["0065353"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Library, Copenhagen University Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Women with endometrial or ovarian cancer experience a variety of symptoms during chemotherapy. Patient-Reported outcomes (PROs) can provide insight into the symptoms they experience. A PRO tool tailored to this patient population can help accurately monitor adverse events and manage symptoms. The objective of this study was to identify items in the National Cancer Institute\u2019s measurement system Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE\u00ae) appropriate for use in a PRO tool for a population of women with endometrial or ovarian cancer undergoing treatment with taxanes (paclitaxel or docetaxel) in combination with carboplatin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A two-phase, sequential multi-methods approach was applied. In phase one, a comprehensive literature search was done to map the toxicity of the applied chemotherapeutics and phase III clinical studies. Phase two, which comprised selecting the PRO-CTCAE items, included discussions with and feedback from a patient advisory board, an additional literature search, and focus group interviews with senior oncologists and specialized oncology nurses. A national expert panel facilitated both phases in terms of carefully select items from the PRO-CTCAE library.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Phase one identified 18 symptoms and phase two, three additional ones, leading to the inclusion of 21 PRO-CTCAE symptoms in the final PRO tool. Since PRO-CTCAE also contains one to three sub-questions on the frequency, severity, and interference with daily activities of symptoms, there were 44 potential items.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study describes taking a multi-method approach to selecting items from the PRO-CTCAE library for use in a population of women with endometrial or ovarian cancer undergoing chemotherapy. By systematically combining diverse approaches, we carefully selected 21 clinically relevant symptoms covered by 44 items in the PRO-CTCAE library. Future studies should investigate the psychometric properties of this PRO tool for women with endometrial or ovarian cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00611-w","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T12:02:33Z","timestamp":1689681753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1507-1130","authenticated-orcid":false,"given":"Mille Guldager","family":"Christiansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-5372","authenticated-orcid":false,"given":"Helle","family":"Pappot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1637-6040","authenticated-orcid":false,"given":"Pernille Tine","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7431-6193","authenticated-orcid":false,"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3040-8384","authenticated-orcid":false,"given":"Mary","family":"Jarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-4674","authenticated-orcid":false,"given":"Karin","family":"Piil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"3","key":"611_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"10177","key":"611_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM (2019) Epithelial ovarian cancer. Lancet 393(10177):1240\u20131253","journal-title":"Lancet"},{"issue":"8","key":"611_CR3","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","volume":"23","author":"I Vergote","year":"2022","unstructured":"Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE et al (2022) Clinical research in ovarian cancer: consensus recommendations from the gynecologic cancer InterGroup. Lancet Oncol 23(8):e374\u2013e384","journal-title":"Lancet Oncol"},{"issue":"3","key":"611_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ygyno.2020.12.021","volume":"160","author":"CA Hamilton","year":"2021","unstructured":"Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT et al (2021) Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations. Gynecol Oncol 160(3):817\u2013826. https:\/\/doi.org\/10.1016\/j.ygyno.2020.12.021","journal-title":"Gynecol Oncol"},{"key":"611_CR5","doi-asserted-by":"publisher","first-page":"viii36","DOI":"10.1093\/annonc\/mdx450","volume":"28","author":"C Marth","year":"2017","unstructured":"Marth C, Reimer D, Zeimet AG (2017) Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Ann Oncol [Internet]. 28:viii36\u2013viii39. https:\/\/doi.org\/10.1093\/annonc\/mdx450","journal-title":"Ann Oncol [Internet]."},{"key":"611_CR6","unstructured":"Dansk Gyn\u00e6kologisk Cancer gruppe. Onkologisk behandling af endometriecancer [Internet]. 2022. http:\/\/www.dgcg.dk\/images\/retningslinier\/Corpuscancer\/DGCG_Onko bh endometrie_ v1.0_AdmGodk030522.pdf"},{"issue":"1","key":"611_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","volume":"31","author":"N Concin","year":"2021","unstructured":"Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S et al (2021) ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12\u201339","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"611_CR8","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1007\/s00520-017-3768-7","volume":"25","author":"HC Hsu","year":"2017","unstructured":"Hsu HC, Tsai SY, Wu SL, Jeang SR, Ho MY, Liou WS et al (2017) Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer. Support Care Cancer 25(11):3457\u20133464","journal-title":"Support Care Cancer"},{"issue":"1","key":"611_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1078155215627502","volume":"23","author":"N Chiu","year":"2017","unstructured":"Chiu N, Chiu L, Chow R, Lam H, Verma S, Pasetka M et al (2017) Taxane-induced arthralgia and myalgia: a literature review. J Oncol Pharm Pract 23(1):56\u201367","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"611_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40271-019-00393-8","volume":"13","author":"ML Martin","year":"2020","unstructured":"Martin ML, Halling K, Eek D, Reaney M (2020) \u201cLower abdominal pains, as if I was being squeezed\u2026in a clamp\u201d: a qualitative analysis of symptoms, patient-perceived side effects and impacts of ovarian cancer. Patient 13(2):189\u2013200. https:\/\/doi.org\/10.1007\/s40271-019-00393-8","journal-title":"Patient"},{"issue":"11","key":"611_CR11","doi-asserted-by":"publisher","first-page":"e007618","DOI":"10.1136\/bmjopen-2015-007618","volume":"5","author":"S Watts","year":"2015","unstructured":"Watts S, Prescott P, Mason J, McLeod N, Lewith G (2015) Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 5(11):e007618","journal-title":"BMJ Open"},{"issue":"4","key":"611_CR12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.esxm.2019.07.005","volume":"7","author":"OJ Fischer","year":"2019","unstructured":"Fischer OJ, Marguerie M, Brotto LA (2019) Sexual function, quality of life, and experiences of women with ovarian cancer: a mixed-methods study. Sex Med 7(4):530\u2013539","journal-title":"Sex Med"},{"issue":"3","key":"611_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"176","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas A, Setser A, Rusch V, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CRR (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 176(3):176\u2013181","journal-title":"Semin Radiat Oncol."},{"key":"611_CR14","doi-asserted-by":"crossref","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National\u2014cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9).","DOI":"10.1093\/jnci\/dju244"},{"issue":"8","key":"611_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza T, Mitchell SA, Reeve B, Castro K, Rogak L (2015) Validity and reliability of the U.S. National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051\u20131059","journal-title":"JAMA Oncol"},{"issue":"2","key":"611_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jpainsymman.2016.02.008","volume":"52","author":"C B\u00e6ksted","year":"2016","unstructured":"B\u00e6ksted C, Nissen A, Pappot H, Bidstrup PE, Mitchell SA, Basch E et al (2016) Danish translation and linguistic validation of the U.S. National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Pain Sympt Manage. 52(2):292\u2013297. https:\/\/doi.org\/10.1016\/j.jpainsymman.2016.02.008","journal-title":"J Pain Sympt Manage."},{"key":"611_CR17","unstructured":"PRO-CTCAE. PRO-CTCAE\u00ae Measurement System website [Internet]. https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"},{"issue":"1","key":"611_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","volume":"18","author":"E Basch","year":"2021","unstructured":"Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P et al (2021) Composite grading algorithm for the national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) Ethan. Clin Trials 18(1):104\u2013114","journal-title":"Clin Trials"},{"issue":"12","key":"611_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrclinonc.2017.153","volume":"14","author":"TW LeBlanc","year":"2017","unstructured":"LeBlanc TW, Abernethy AP (2017) Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. Nat Rev Clin Oncol 14(12):763\u2013772","journal-title":"Nat Rev Clin Oncol"},{"key":"611_CR20","unstructured":"FDA, HHS. Guidance for industry use in medical product development to support labeling claims guidance for industry. Clin Fed Regist. 2009;1\u201339."},{"issue":"2","key":"611_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C et al (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA J Am Med Assoc 318(2):197\u2013198","journal-title":"JAMA J Am Med Assoc"},{"issue":"6","key":"611_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/0284186X.2020.1749880","volume":"59","author":"H Pappot","year":"2020","unstructured":"Pappot H, Taarnh\u00f8j GA (2020) Expectations to patient-reported outcome (PRO) in Oncology\u2013PRO for a purpose, when and how? Acta Oncol 59(6):611\u2013612. https:\/\/doi.org\/10.1080\/0284186X.2020.1749880","journal-title":"Acta Oncol"},{"issue":"9","key":"611_CR23","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1097\/IGC.0000000000000551","volume":"25","author":"S Soo Hoo","year":"2015","unstructured":"Soo Hoo S, Marriott N, Houlton A, Nevin J, Balega J, Singh K et al (2015) Patient-reported outcomes after extensive (ultraradical) surgery for ovarian cancer: results from a prospective longitudinal feasibility study. Int J Gynecol Cancer 25(9):1599\u20131607","journal-title":"Int J Gynecol Cancer"},{"key":"611_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1200\/JCO.20.02015","volume":"39","author":"K Absolom","year":"2021","unstructured":"Absolom K, Warrington L, Hudson E, Hewison J, Morris C, Holch P et al (2021) Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy. J Clin Oncol 39:734","journal-title":"J Clin Oncol"},{"issue":"6","key":"611_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557\u2013565","journal-title":"J Clin Oncol"},{"key":"611_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09817-5","author":"F Kennedy","year":"2022","unstructured":"Kennedy F, Shearsmith L, Holmes M, Rogers Z, Carter R, Hofmann U et al (2022) Electronic patient\u2014reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-022-09817-5","journal-title":"BMC Cancer"},{"issue":"78","key":"611_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2017.03.019","volume":"2017","author":"F Joly","year":"2017","unstructured":"Joly F, Hilpert F, Okamoto A, Stuart G, Ochiai K, Friedlander M (2017) Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. Eur J Cancer 2017(78):133\u2013138. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.019","journal-title":"Eur J Cancer"},{"issue":"9","key":"611_CR28","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","volume":"33","author":"M Di Maio","year":"2022","unstructured":"Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D et al (2022) The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. Ann Oncol 33(9):878","journal-title":"Ann Oncol"},{"issue":"5","key":"611_CR29","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/0284186X.2018.1560496","volume":"58","author":"A Nissen","year":"2019","unstructured":"Nissen A, Bager L, Pappot H (2019) The use of PRO in adverse event identification during cancer therapy\u2013choosing the right questions to ask. Acta Oncol (Madr). 58(5):596\u2013602. https:\/\/doi.org\/10.1080\/0284186X.2018.1560496","journal-title":"Acta Oncol (Madr)."},{"issue":"6","key":"611_CR30","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s11135-018-0700-2","volume":"52","author":"MT Anguera","year":"2018","unstructured":"Anguera MT, Blanco-Villase\u00f1or A, Losada JL, S\u00e1nchez-Algarra P, Onwuegbuzie AJ (2018) Revisiting the difference between mixed methods and multimethods: Is it all in the name? Qual Quant 52(6):2757\u20132770","journal-title":"Qual Quant"},{"issue":"1","key":"611_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-019-0141-2","volume":"3","author":"GA Taarnh\u00f8j","year":"2019","unstructured":"Taarnh\u00f8j GA, Lindberg H, Johansen C, Pappot H (2019) Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy. J Patient-Rep Outcomes. 3(1):1\u20139","journal-title":"J Patient-Rep Outcomes."},{"issue":"1","key":"611_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-019-0111-8","volume":"3","author":"LK Tolstrup","year":"2019","unstructured":"Tolstrup LK, Bastholt L, Zwisler AD, Dieperink KB, Pappot H (2019) Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. J Patient-Rep Outcomes 3(1):1\u20137","journal-title":"J Patient-Rep Outcomes"},{"issue":"1","key":"611_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s41687-021-00326-w","volume":"5","author":"PK M\u00f8ller","year":"2021","unstructured":"M\u00f8ller PK, Pappot H, Bernchou U, Schytte T, Dieperink KB (2021) Development of patient-reported outcomes item set to evaluate acute treatment toxicity to pelvic online magnetic resonance-guided radiotherapy. J Patient-Rep Outcomes. 5(1):47. https:\/\/doi.org\/10.1186\/s41687-021-00326-w","journal-title":"J Patient-Rep Outcomes."},{"key":"611_CR34","doi-asserted-by":"crossref","unstructured":"Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2 reporting checklists: Tools to improve reporting of patient and public involvement in research. BMJ. 2017;358.","DOI":"10.1136\/bmj.j3453"},{"issue":"13","key":"611_CR35","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD (2016) Sample size in qualitative interview studies: guided by information power. Qual Health Res 26(13):1753\u20131760","journal-title":"Qual Health Res"},{"key":"611_CR36","unstructured":"Krueger R, Casey MA. Focus Groups\u2014a practical guide for applied research. California Publications, 472 SAGE; 2015"},{"key":"611_CR37","unstructured":"European Medicines Agency (EMA) [Internet]. [cited 2022 Oct 13]. https:\/\/www.ema.europa.eu\/en"},{"key":"611_CR38","unstructured":"The Food and Drug Administration (FDA) [Internet]. [cited 2022 Oct 1]. https:\/\/www.fda.gov\/"},{"key":"611_CR39","unstructured":"Medical Dictionary for Regulatory Activities (MEDDRA) [Internet]. [cited 2022 Nov 10]. https:\/\/www.meddra.org\/"},{"issue":"4","key":"611_CR40","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1177\/0890334420949218","volume":"36","author":"SL Gill","year":"2020","unstructured":"Gill SL (2020) Qualitative sampling methods. J Hum Lact 36(4):579\u2013581","journal-title":"J Hum Lact"},{"key":"611_CR41","doi-asserted-by":"crossref","unstructured":"Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014;106(7).","DOI":"10.1093\/jnci\/dju129"},{"issue":"7","key":"611_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/jnci\/dju128","volume":"106","author":"KA Donovan","year":"2014","unstructured":"Donovan KA, Donovan HS, Cella D, Gaines ME, Penson RT, Plaxe SC et al (2014) Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst 106(7):10\u201313","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"611_CR43","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/IGC.0000000000000167","volume":"24","author":"MT King","year":"2014","unstructured":"King MT, Stockler MR, Butow P, O\u2019Connell R, Voysey M, Oza AM et al (2014) Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. Int J Gynecol Cancer 24(5):865\u2013873","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"611_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11136-017-1729-8","volume":"27","author":"MT King","year":"2018","unstructured":"King MT, Stockler MR, O\u2019Connell RL, Buizen L, Joly F, Lanceley A et al (2018) Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Qual Life Res 27(1):59\u201374","journal-title":"Qual Life Res"},{"key":"611_CR45","doi-asserted-by":"publisher","unstructured":"Webster EM, Burke WM, Ware HM, Jones BA, Vattakalam R, Tergas AI, et al. Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study. Gynecol Oncol [Internet]. 2018;150(3):487\u201393. Available from: http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.008","DOI":"10.1016\/j.ygyno.2018.07.008"},{"issue":"22","key":"611_CR46","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherpy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682\u20131691","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"611_CR47","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21(17):3194\u20133200","journal-title":"J Clin Oncol"},{"issue":"17","key":"611_CR48","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, L\u00fcck HJ, Meier W, Adams HP, M\u00f6bus V, Costa S et al (2003) A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320\u20131330","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"611_CR49","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s00520-021-06589-9","volume":"30","author":"MT Alanazi","year":"2022","unstructured":"Alanazi MT, Alanazi NT, Alfadeel MA, Bugis BA (2022) Sleep deprivation and quality of life among uterine cancer survivors: systematic review. Support Care Cancer 30(3):2891\u20132900. https:\/\/doi.org\/10.1007\/s00520-021-06589-9","journal-title":"Support Care Cancer"},{"issue":"3","key":"611_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jsr.13510","volume":"31","author":"L Palagini","year":"2022","unstructured":"Palagini L, Miniati M, Massa L, Folesani F, Marazziti D, Grassi L et al (2022) Insomnia and circadian sleep disorders in ovarian cancer: evaluation and management of underestimated modifiable factors potentially contributing to morbidity. J Sleep Res 31(3):1\u201313","journal-title":"J Sleep Res"},{"issue":"1","key":"611_CR51","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygyno.2021.01.026","volume":"161","author":"AC Pizzoferrato","year":"2021","unstructured":"Pizzoferrato AC, Klein M, Fauvet R, Durand C, Foucher F, Sardain H et al (2021) Pelvic floor disorders and sexuality in women with ovarian cancer: a systematic review. Gynecol Oncol 161(1):264\u2013274","journal-title":"Gynecol Oncol"},{"key":"611_CR52","doi-asserted-by":"publisher","first-page":"642382","DOI":"10.3389\/fonc.2021.642382","volume":"11","author":"EY Ibrahim","year":"2021","unstructured":"Ibrahim EY, Domenicano I, Nyhan K, Elfil M, Mougalian SS, Cartmel B et al (2021) Cognitive effects and depression associated with taxane-based chemotherapy in breast cancer survivors: a meta-analysis. Front Oncol 11:642382","journal-title":"Front Oncol"},{"issue":"2","key":"611_CR53","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.soncn.2019.02.008","volume":"35","author":"MG Harris","year":"2019","unstructured":"Harris MG (2019) Sexuality and menopause: unique issues in gynecologic cancer. Semin Oncol Nurs 35(2):211\u2013216. https:\/\/doi.org\/10.1016\/j.soncn.2019.02.008","journal-title":"Semin Oncol Nurs"},{"issue":"3","key":"611_CR54","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00404-021-06056-0","volume":"304","author":"M Roussin","year":"2021","unstructured":"Roussin M, Lowe J, Hamilton A, Martin L (2021) Factors of sexual quality of life in gynaecological cancers: a systematic literature review. Arch Gynecol Obstet 304(3):791\u2013805. https:\/\/doi.org\/10.1007\/s00404-021-06056-0","journal-title":"Arch Gynecol Obstet"},{"key":"611_CR55","doi-asserted-by":"publisher","first-page":"107412","DOI":"10.1016\/j.ypmed.2022.107412","volume":"167","author":"RJ Bergin","year":"2023","unstructured":"Bergin RJ, Short CE, Davis N, Marker J, Dawson MT, Milton S et al (2023) The nature and impact of patient and public involvement in cancer prevention, screening and early detection research: a systematic review. Prev Med (Baltim). 167:107412. https:\/\/doi.org\/10.1016\/j.ypmed.2022.107412","journal-title":"Prev Med (Baltim)."},{"issue":"11","key":"611_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12113296","volume":"12","author":"G Bhat","year":"2020","unstructured":"Bhat G, Karakasis K, Oza AM (2020) Measuring quality of life in ovarian cancer clinical trials: Can we improve objectivity and cross trial comparisons? Cancers (Basel) 12(11):1\u201324","journal-title":"Cancers (Basel)"},{"issue":"7","key":"611_CR57","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.pec.2021.11.020","volume":"105","author":"J Galica","year":"2022","unstructured":"Galica J, Saunders S, Romkey-Sinasac C, Silva A, Ethier JL, Giroux J et al (2022) The needs of gynecological cancer survivors at the end of primary treatment: a scoping review and proposed model to guide clinical discussions. Patient Educ Couns 105(7):1761\u20131782. https:\/\/doi.org\/10.1016\/j.pec.2021.11.020","journal-title":"Patient Educ Couns"},{"issue":"1","key":"611_CR58","doi-asserted-by":"publisher","first-page":"E27","DOI":"10.1097\/NCC.0000000000000860","volume":"45","author":"YJ Lee","year":"2021","unstructured":"Lee YJ, Park A, Roberge M, Donovan H (2021) What can social media tell us about patient symptoms: a text-mining approach to online ovarian cancer forum. Cancer Nurs 45(1):E27-35","journal-title":"Cancer Nurs"},{"issue":"3","key":"611_CR59","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1093\/pubmed\/fdx188","volume":"40","author":"MM Koo","year":"2018","unstructured":"Koo MM, von Wagner C, Abel GA, McPhail S, Hamilton W, Rubin GP et al (2018) The nature and frequency of abdominal symptoms in cancer patients and their associations with time to help-seeking: evidence from a national audit of cancer diagnosis. J Public Health (Oxf) 40(3):e388\u2013e395","journal-title":"J Public Health (Oxf)"},{"issue":"2","key":"611_CR60","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ygyno.2005.06.062","volume":"99","author":"HS Donovan","year":"2005","unstructured":"Donovan HS, Hartenbach EM, Method MW (2005) Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer. Gynecol Oncol 99(2):404\u2013411","journal-title":"Gynecol Oncol"},{"key":"611_CR61","first-page":"1","volume":"27599","author":"E Basch","year":"2022","unstructured":"Basch E, Schrag D, Henson S, Jansen J, Ginos B, Stover AM et al (2022) Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer. JAMA 27599:1\u201310","journal-title":"JAMA"},{"key":"611_CR62","unstructured":"GCIG Gynecologic Cancer Intergroup [Internet]. [cited 2022 Nov 23]. https:\/\/gcigtrials.org\/content\/most"},{"key":"611_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.17.00149","volume":"2","author":"AA Wright","year":"2018","unstructured":"Wright AA, Raman N, Staples P, Schonholz S, Cronin A, Carlson K et al (2018) The HOPE pilot study: harnessing patient-reported outcomes and biometric data to enhance cancer care. JCO Clin Cancer Inform 2:1\u201312","journal-title":"JCO Clin Cancer Inform"},{"issue":"2","key":"611_CR64","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/tbj.13204","volume":"25","author":"H Pappot","year":"2019","unstructured":"Pappot H, B\u00e6ksted C, Knoop A, Mitchell SA, Nissen A, Johansen C (2019) Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients: organization and design of the first national, cluster randomized trial using the patient-reported outcomes version of common terminology C. Breast J 25(2):269\u2013272","journal-title":"Breast J"},{"issue":"2","key":"611_CR65","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ygyno.2021.12.006","volume":"164","author":"VL Beesley","year":"2022","unstructured":"Beesley VL, Ross TL, King MT, Campbell R, Nagle CM, Obermair A et al (2022) Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns). Gynecol Oncol 164(2):437\u2013445. https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.006","journal-title":"Gynecol Oncol"},{"key":"611_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PROM.S272688","volume":"12","author":"S Boban","year":"2021","unstructured":"Boban S, Downs J, Codde J, Cohen PA, Bulsara C (2021) Women diagnosed with ovarian cancer: patient and carer experiences and perspectives. Patient Relat Outcome Meas 12:33\u201343","journal-title":"Patient Relat Outcome Meas"},{"issue":"4","key":"611_CR67","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ajog.2017.04.012","volume":"217","author":"M Whicker","year":"2017","unstructured":"Whicker M, Black J, Altwerger G, Menderes G, Feinberg J, Ratner E (2017) Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am J Obstet Gynecol 217(4):395\u2013403. https:\/\/doi.org\/10.1016\/j.ajog.2017.04.012","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"611_CR68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10147-018-1319-y","volume":"24","author":"S Komiyama","year":"2019","unstructured":"Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A et al (2019) Bevacizumab combined with platinum\u2013taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Int J Clin Oncol 24(1):103\u2013114. https:\/\/doi.org\/10.1007\/s10147-018-1319-y","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"611_CR69","first-page":"4005","volume":"37","author":"N Biglia","year":"2017","unstructured":"Biglia N, Zanfagnin V, Daniele A, Robba E, Bounous VE (2017) Lower body lymphedema in patients with gynecologic cancer. Anticancer Res 37(8):4005\u20134015","journal-title":"Anticancer Res"},{"issue":"2","key":"611_CR70","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/ijgc-2019-001032","volume":"30","author":"K Dessources","year":"2020","unstructured":"Dessources K, Aviki E, Leitao MM (2020) Lower extremity lymphedema in patients with gynecologic malignancies. Int J Gynecol Cancer 30(2):252\u2013260","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"611_CR71","doi-asserted-by":"publisher","first-page":"90.e1","DOI":"10.1016\/j.ajog.2021.08.01","volume":"226","author":"D Forsse","year":"2022","unstructured":"Forsse D, Barbero ML, Werner HMJ, Woie K, Nordskar N, Berge Nilsen E et al (2022) Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. Am J Obstet Gynecol 226(1):90.e1-90.e20. https:\/\/doi.org\/10.1016\/j.ajog.2021.08.01","journal-title":"Am J Obstet Gynecol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00611-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00611-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00611-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T12:06:24Z","timestamp":1689681984000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00611-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00611-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and is registered with the Danish Data Protection Agency (P-2021- 179). All study participants were informed of the purpose of this study and provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}